Tag Archives: Jim Birchenough

Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Wells Fargo

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed last Monday at $68.94, close to its 52-week high of $74.00. According to TipRanks.com, Birchenough is a 5-star

Wells Fargo Remains a Buy on Ionis Pharmaceuticals Inc (IONS)

In a report released today, Jim Birchenough from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals Inc (IONS – Research Report). The company’s shares closed last Monday at $61.11. According to TipRanks.com, Birchenough is a 5-star analyst with an

Celgene (CELG) Gets a Hold Rating from Wells Fargo

Wells Fargo analyst Jim Birchenough maintained a Hold rating on Celgene (CELG – Research Report) today. The company’s shares opened today at $87.86. According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 19.9% and a 46.8%

Autolus Therapeutics Plc (AUTL) Gets a Buy Rating from Wells Fargo

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Autolus Therapeutics Plc (AUTL – Research Report) yesterday. The company’s shares closed yesterday at $39.93. According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 22.5% and

Wells Fargo Sticks to Their Buy Rating for Immunomedics (IMMU)

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Immunomedics (NASDAQ: IMMU) yesterday. The company’s shares closed yesterday at $21.35. According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 21.5% and a 46.7% success rate.

Wells Fargo Starts Global Blood Therapeutics (GBT) with a Strong Upside

Drug capsuls

Global Blood Therapeutics Inc (NASDAQ:GBT) surged over 12.7% on September 30th, 2016 to $23.05 as Wells Fargo analysts initiated a coverage on the group with an Outperform rating. The analysts, led by Jim Birchenough, estimate a $75 to $81 valuation